Alkermes (ALKS) Long-Term Investments (2011 - 2026)
Alkermes (ALKS) posted quarterly Long-Term Investments of $26.4 million for Q1 2026, down 18.1% YoY from $32.2 million in Q1 2025, and up 18081.38% sequentially from $145000.0 in Q4 2025.
Alkermes (ALKS) Long-Term Investments (2011 - 2026) Analysis & Trends
Alkermes has disclosed Long-Term Investments across 16 years of filings, most recently posting $26.4 million for Q1 2026.
- In Q1 2026, Long-Term Investments fell 18.1% year-over-year to $26.4 million; the TTM figure through Mar 2026 stood at $26.4 million (down 18.1% YoY), while the FY2025 annual figure was $145000.0, down 99.8% from the prior year.
- Long-Term Investments grew to $26.4 million in Q1 2026, from $145000.0 in the prior quarter.
- Over the last five years, Long-Term Investments for ALKS reached as high as $229.8 million in Q1 2022 and fell as low as $145000.0 in Q4 2025.
- The 5-year median for Long-Term Investments is $73.1 million (2024), against an average of $81.8 million.
- Annual changes were most pronounced in 2022 — Long-Term Investments soared 165.85% — and 2025, when it plunged 99.8%.
- A 5-year view of Long-Term Investments shows it stood at $131.6 million in 2022, then tumbled by 69.69% to $39.9 million in 2023, then jumped by 83.39% to $73.1 million in 2024, then sank by 99.8% to $145000.0 in 2025, then soared by 18081.38% to $26.4 million in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $26.4 million, $145000.0, and $27.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.67 Bn | 34.93 Bn | 1.97 Bn | - |
| 2 | Zoetis | 30.59 Bn | 28.65 Bn | 1.62 Bn | - |
| 3 | RedHill Biopharma | 26.22 Bn | 26.22 Bn | - | 12.05 Mn |
| 4 | United Therapeutics | 23.80 Bn | 21.65 Bn | 648.10 Mn | 1.32 Bn |
| 5 | Curaleaf Holdings | 23.70 Bn | 23.70 Bn | 157.29 Mn | - |
| 6 | Viatris | 18.69 Bn | 16.89 Bn | 1.16 Bn | - |
| 7 | Neurocrine Biosciences | 16.86 Bn | 15.54 Bn | 800.70 Mn | 1.33 Bn |
| 8 | Elanco Animal Health | 11.99 Bn | 11.57 Bn | 785.00 Mn | - |
| 9 | Dr Reddys Laboratories | 11.65 Bn | 11.51 Bn | - | 114.00 Mn |
| 10 | Alkermes | 94.96 Mn | -416.90 Mn | -116.06 Mn | 26.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.36 Mn |
| Dec 31, 2025 | 145,000.00 |
| Sep 30, 2025 | 27.87 Mn |
| Jun 30, 2025 | 38.27 Mn |
| Mar 31, 2025 | 32.19 Mn |
| Dec 31, 2024 | 73.15 Mn |
| Sep 30, 2024 | 18.92 Mn |
| Jun 30, 2024 | 86.40 Mn |
| Mar 31, 2024 | 62.78 Mn |
| Dec 31, 2023 | 39.89 Mn |
| Sep 30, 2023 | 106.43 Mn |
| Jun 30, 2023 | 78.13 Mn |
| Mar 31, 2023 | 92.08 Mn |
| Dec 31, 2022 | 131.61 Mn |
| Sep 30, 2022 | 166.93 Mn |
| Jun 30, 2022 | 179.01 Mn |
| Mar 31, 2022 | 229.83 Mn |
| Dec 31, 2021 | 229.43 Mn |
| Sep 30, 2021 | 187.86 Mn |
| Jun 30, 2021 | 131.03 Mn |